Novel Potent Analgesic peptides derived from a endogenous protein to treat severe pain

A novel peptide-based pain-killer derived from an endogenous protein exhibits :

• A higher level of analgesia than morphine
• A peripheral indirect opioidergic activity with a long lasting effect

TECHNOLOGY

• Peptide 4 shows at least 2 folds stronger analgesia than morphine on animal models at 4 hours (Von Frey Tests, intrathecal administration,
• Peptide 4 displays a much better analgesic activity than morphine, at low doses (10 nm) in neuropathic model (n=10) with IP injection

APPLICATION

Treatment of moderate to severe pain, especially under chronic conditions.

INNOVATION ADVANTAGES

• Peptide 4 exhibits greater analgesia than morphine on neuropathic models
• Indirect opioidergic activity (Onset of 2-3 hours)
• Long lasting effect
• Endogenous ! (No immunogenicity)
• Peripheral activity only (Tolerance +, side effect +)

DEVELOPMENT STATUS

• MOA currently deeeply investigated
• Program founded by Conectus in preparation, including: Early PK/TOX; In-Vivo efficacy on different pain Models; tolerance & side effects vs morphine; efficacy vs morphine.